Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | BLM | P54132 | 3/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | HTR1A | P08908 | 2/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382361 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL30405928 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL5493779 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL454983 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL19871231 | 1.00 | KMT2A (0.73) | KMT2ABLMHTR2AKDM4ELMNA | |
| Tryptophan SCHEMBL7091652 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| D-Tryptophan SCHEMBL8103547 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| Tryptophan SCHEMBL7091650 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| D-Tryptophan SCHEMBL8103544 | 0.94 | KMT2A (0.78) | KMT2ABLMHTR2AKDM4ELMNA | |
| SCHEMBL28473836 | 0.93 | HTR2A (0.64) | KMT2ABLMHTR2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-12203115-B2 | Universal platform for genetic code expansion | TRUSTEES OF BOSTON COLLEGE (US) | 2025-01-21 | — | — | US | claimed |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-14 | — | — | US | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116836959-A | Enzyme composition for synthesizing neomycin derivative and application thereof | 山东大学 | 2023-10-03 | — | — | CN | claimed |
| CN-116806149-A | Methods and compositions for treating pathological conditions involving neovascularization using IDO 1-dependent angiogenic cells | 兰肯瑙医学研究所 | 2023-09-26 | — | — | CN | claimed |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-12 | — | — | US | claimed |
| US-20230175013-A1 | CONTROLLED MODIFICATION OF ADENO-ASSOCIATED VIRUS (AAV) FOR ENHANCED GENE THERAPY | NATIONAL SCIENCE FOUNDATION | 2023-06-08 | — | — | US | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| EP-2260846-A1 | Novel methods for the treatment of cancer | Lankenau Institute for Medical Research (US) | 2010-12-15 | — | — | EP | claimed |
| WO-2010008427-A1 | TRYPTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2010-01-21 | — | — | WO | claimed |
| EP-1613308-A4 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INST MEDICAL RES (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2007054348-A1 | NOVEL MEDICAMENTS | Ernst-Moritz-Arndt-Universität Greifswald (DE) | 2007-05-18 | — | — | WO | claimed |
| US-20070099844-A1 | Novel methods for the treatment of cancer | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-03 | — | — | US | claimed |
| CN-1794986-A | Novel methods for the treatment of cancer | LANKENAU INST MEDICAL RES (US) | 2006-06-28 | — | — | CN | claimed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1219603-A2 | Tryptophan analogs in proteins, peptides and peptidic structures | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2002-07-03 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | KMT2A 1848/4885BLM 3782/4885HTR2A 3159/4885 |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | IDO1, IDO2, TIE1 | KMT2A 2568/4885BLM 2636/4885HTR2A 3120/4885 |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | IDO1, IDO2, GPR119 | KMT2A 1002/4885BLM 3908/4885HTR2A 210/4885 |
| US-20230175013-A1 | CONTROLLED MODIFICATION OF ADENO-ASSOCIATED VIRUS (AAV) FOR ENHANCED GENE THERAPY | AAAS, ATIC, NPEPPS | KMT2A 325/4885BLM 4797/4885HTR2A 2859/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | KMT2A 1523/4885BLM 4137/4885HTR2A 3608/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | KMT2A 2188/4885BLM 4297/4885HTR2A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.